Study register · detailSystematic Review · Ulcerative Colitis · 2024
Phytotherapeutic recommendations in medical guidelines for the treatment of gastroenterological diseases - a systematic review
Utz et al.·Zeitschrift fur GastroenterologieImpact 0.2
MixedGRADEHigh5 citations
SampleSystematische Review
EndpointGuideline recommendations
Blindingunklar
DesignSystematic Review
”Key finding
Phytotherapeutics show varying levels of evidence for different gastroenterological diseases: strong recommendation for peppermint oil in irritable bowel syndrome, recommendations for further phytotherapeutics in constipation and ulcerative colitis, but insufficient data for Crohn's disease and a need for further methodologically high-quality studies.
Summary
Systematic screening of phytotherapeutic recommendations in gastroenterological guidelines. For ulcerative colitis: Plantago psyllium as well as the combination of myrrh/chamomile flower extract/coffee charcoal as a complement for maintaining remission; 'open recommendation' for curcumin (induction and maintenance of remission). Cannabis-based medicines may be considered for abdominal pain/loss of appetite if standard therapy is ineffective; not for acute inflammation.
InterventionPhytotherapeutics including cannabis-based medicines (various preparations/applications)
O
OutcomeGuideline recommendations for phytotherapeutics of varying strength; cannabis-based medicines as an option for abdominal pain and relevant loss of appetite in case of failure/contraindication of standard therapy, not for acute inflammation in active Crohn's disease
Confidence in the evidence
Very lowLowModerateHigh
High
The highest of four GRADE levels, the effect estimate is very reliable.
Phytotherapeutics are gaining influence in the treatment of gastroenterological diseases. Their popularity and growing evidence of efficacy contribute to their integration into medical guidelines. A systematic screening identified recommended phytotherapeutic approaches. Based on current scientific data, some recommendations for the use of phytotherapeutic agents are given. For irritable bowel syndrome the use of peppermint oil is "strongly recommended", especially for pain and flatulence. Other phytotherapeutics such as STW-5, Tibetan Padma Lax or warm caraway oil pads have proven effective in alleviating symptoms. It is "recommended" to integrate them into the treatment concept. For chronic constipation, 30g of fiber per day is recommended. Best data exists for plantago psyllium with moderate evidence and chicory inulin. In case of ulcerative colitis, plantago psyllium as well as the combination of myrrh, chamomile flower extract, and coffee charcoal can be used as a complementary treatment in maintaining remission. There is also an "open recommendation" for curcumin for both, remission induction and maintenance. Some phytotherapeutic treatments (e.g., Artemisia absintium, Boswellia serata) show evidence of effectiveness for the treatment of Crohn's disease, but data are not yet sufficient for recommendations. Cannabis-based medicines can be considered for abdominal pain and clinically relevant appetite loss if standard therapy is ineffective or contraindicated, but they should not be used for acute inflammation in active Crohn's disease. Further recommendations for other gastroenterological diseases are discussed. The safety and tolerability of the phytotherapeutics were rated as predominantly "very good" to "acceptable". Some clear recommendations for the use of phytotherapeutics to treat gastroenterological diseases show their great potential. Due to their wide range of effects, phytotherapeutics can be used very well as a complement to conventional medicines in case of complex regulatory disorders. However, further methodologically well-conducted impact studies would be helpful in order to be able to make further recommendations.